GlucoTrack, Inc.

7.30+0.56 (+8.23%)

Oct 28, 4:00:01 PM EDT · NasdaqCM · GCTK · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

6.65M

P/E (TTM)

Basic EPS (TTM)

-2441.21

Dividend Yield

Recent Filings

8-K

10/28/25Oct 28, 2025

8-K

Glucotrack issues $3M note

9/12/25Sep 12, 2025

Glucotrack secured $3 million in funding on September 12, 2025, via a zero-interest convertible promissory note with a $3.6 million principal, carrying a $600,000 original issue discount; it matures in 12 months or upon a qualified financing exceeding $5 million, with conversion at the financing price but no lower than $4.87 per share. Proceeds tie to an existing $20 million equity line of credit, mandating full repayment from initial draws until stockholder approval, then half thereafter. This bolsters liquidity while granting the investor a 25% participation right in future offerings. Default risks include bankruptcy triggers demanding immediate repayment.

8-K

Glucotrack secures $20M equity line

9/11/25Sep 11, 2025

Glucotrack inked a deal on September 11, 2025, with Sixth Borough Capital Fund for up to $20 million in common stock sales over 24 months, via regular, add-on, and intraday purchases at discounted VWAP rates. The pact includes a 1.5% commitment fee payable in cash or shares, with proceeds earmarked for working capital and general corporate needs. Yet dilution looms large, capped initially at 19.99% of outstanding shares without stockholder nod.

8-K

Q2 2025 results and CBGM progress

8/14/25Aug 14, 2025

Glucotrack reported a $11.6 million net loss for the six months ended June 30, 2025, up from $7.4 million last year, driven by a $3.3 million non-cash derivative liability charge and higher operating expenses, yet bolstered cash to $9.6 million via equity raises. The company advanced its implantable CBGM with positive first-in-human study results showing 7.7% MARD accuracy and no serious adverse events. On track for Australian trial implants in Q3 2025. Cash funds operations through year-end.

10-Q

Q2 FY2025 results

8/14/25Aug 14, 2025

Glucotrack posted an operating loss of $4.8M for Q2 FY2025 ended June 30, 2025, up 6.8% y/y from $4.5M yet down from $3.4M in Q1 (derived), driven by higher general and administrative costs on legal fees and personnel, while research expenses dipped 12.2% y/y to $3.2M amid lower manufacturing accruals. Net loss widened to $4.8M from $4.5M y/y, with the gap to operating loss under 20% tied to a $95K warrant repurchase loss. Cash swelled to $9.6M after $10.7M from equity offerings, funding a first-in-human study that hit all endpoints with 7.7% MARD accuracy; a long-term trial starts Q3 outside the US, with FDA IDE filing eyed for Q4. Cash burn hit $6.7M YTD, no FCF as capex was minor. Reverse splits in February and June adjusted shares. Regulatory hurdles could stall trials.

About

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

CEO

Dr. Paul V. Goode Ph.D.

IPO

4/25/2013

Website

https://glucotrack.com

Employees

Sector

Healthcare

Industry

Medical Instruments & Supplies